Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects With Advanced Solid Tumors

NCT06873659 is registered in ClinicalTrials.gov with Qurgen Inc. as lead sponsor.

NCT NCT06873659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06873659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects With Advanced Solid Tumors
Lead sponsor
Qurgen Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 26, 2025
Completion date
November 30, 2027
Enrollment
96 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, liver cancer, solid tumor